Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sign Of The Times: Late-Stage Cancer Vaccines On Display At ASCO

This article was originally published in The Pink Sheet Daily

Executive Summary

Vindicated by the approvals of Provenge and Yervoy, a host of therapeutic cancer vaccines is working through late-stage trials with the regulatory finish line in sight, and some of those companies will be presenting data at the American Society of Clinical Oncology meeting in Chicago June 1-5.

You may also be interested in...



Generex Likes Chances For Partnering AE37 Breast Cancer Vaccine

The vaccine trains specialized immune cells to act against a HER2 peptide. Created using Antigen Express’ Ii-Key Hybrid platform, Generex says AE37 has none of the restrictions that will limit the market potential of other HER2 peptide vaccines in development.

In Europe, A Public-Private Effort Could Shed Light On The Tricky Business Of Cancer Vaccines

With EU cash in hand, the GAPVAC consortium aims to develop tailor-made vaccines for patients with the rare but aggressive brain cancer, glioblastoma. The vaccines will be unique to each individual, but hopefully with increased efficacy compared with other therapies, thereby justifying the likely higher cost and complexity of treatment.

New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines

A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS074137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel